The use of combinations of monoclonal antibodies in clinical oncology

Linda M. Henricks, Jan H.M. Schellens, Alwin D.R. Huitema, Jos H. Beijnen

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

73 Citaten (Scopus)

Samenvatting

Treatment with monoclonal antibodies is becoming increasingly important in clinical oncology. These antibodies specifically inhibit signaling pathways in tumor growth and/or induce immunological responses against tumor cells. By combining monoclonal antibodies several pathways may be targeted simultaneously, potentially leading to additive or synergistic effects. Theoretically, antibodies are very suitable for use in combination therapy, because of limited overlapping toxicity and lack of pharmacokinetic interactions. In this article an overview is given of preclinical and clinical data on twenty-five different combinations of antibodies in oncology. Some of these combinations have proven clinical benefit, for example the combination of trastuzumab and pertuzumab in HER2-positive breast cancer, which exemplifies an additive or synergistic effect on antitumor activity in clinical studies and the combination of nivolumab and ipilimumab, which results in significant increases in progression-free and overall survival in patients with advanced melanoma. However, other combinations may lead to unfavorable results, such as bevacizumab with cetuximab or panitumumab in advanced colorectal cancer. These combinations result in shorter progression-free survival and increased toxicity compared to therapy with a single antibody. In summary, the different published studies showed widely varying results, depending on the combination of antibodies, indication and patient population. More preclinical and clinical studies are necessary to unravel the mechanisms behind synergistic or antagonistic effects of combining monoclonal antibodies. Most research on combination therapies is still in an early stage, but it is expected that for several tumor types the use of combination therapy of antibodies will become standard of care in the near future.

Originele taal-2Engels
Pagina's (van-tot)859-867
Aantal pagina's9
TijdschriftCancer Treatment Reviews
Volume41
Nummer van het tijdschrift10
DOI's
StatusGepubliceerd - 2015
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'The use of combinations of monoclonal antibodies in clinical oncology'. Samen vormen ze een unieke vingerafdruk.

Citeer dit